Nature Communications

Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial

2026-05-08

Full text

DOI https://doi.org/10.1038/s41467-026-72242-w